Josh Genuth, Author at PsyNews.com

Home Authors Posts by Watertime

521 POSTS 0 COMMENTS

So, You Want to Participate in a Psychedelic Clinical Trial

Why Ayahuasca Is Miley Cyrus’ ‘Favorite’ Drug

New Research Compares Placebo and Psychedelic Microdosing Benefits

Psychedelic Business News Spotlight: February 5, 2021

2 Massachusetts Cities Have Decriminalized Psychedelics in the Last Month

Interview With Dr. Hyder A. Khoja

Interview With Yaron Conforti, Novamind

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters

1...474849...53 Page 48 of 53

EDITOR PICKS

Q1 2026: Oregon Psilocybin Services Update

Psychedelic Funding Update: Q2 2026

Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime